05), whereas the difference in AUC0−30 of the two formulations wa

05), whereas the difference in AUC0−30 of the two formulations was found to be significant (P < 0.05). The AUC0−30 values were 130.9 ± 4.9 μg h/ml and 135.8 ± 2.5 μg h/ml

for F10 and Hifenac SR respectively and the difference between AUC0−30 values of F10 (130.9 ± 4.9) and Hifenac SR (135.8 ± 2.5) was 3.74%. The percentage deviation observed for formulation (F10) and marketed product (Hifenac SR) tablets was within the range of 80–125% with respect to Cmax, Tmax and AUC values, which is a general regulatory requirement for tablets to be bioequivalent. Park et al10 evaluated the effects of PEG or PEO on matrix properties of tablets. Based on their optimization model for drug release, they reported that the optimal settings in matrix tablets were 124.3 mg and 110 mg

for PEG and PEO respectively. Petrovi et al11 developed artificial intelligence methods for the optimization Pomalidomide manufacturer of drug release from matrix tablets, using diclofenac Decitabine molecular weight sodium and caffeine as model drugs and polyethylene oxide and glyceryl palmitostearate as matrix forming materials, for hydrophilic and lipid matrix tablets respectively. Petrovi et al12 have also studied the use of dynamic neural networks to predict the release of diclofenac sodium from PEO matrix tablets. They reported that dynamic neural networks are superior to static networks. Mohsen et al13 developed and evaluated sustained release matrix tablets of aceclofenac with Eudragit® RSPO and Eudragit® RLPO. These tablets released aceclofenac up to 24 h in vitro and exhibited longer MRT when compared to commercial product of aceclofenac (Bristaflam®), when studied in albino rabbits. Yadav et al 14 carried out the formulation, evaluation enough and optimization of aceclofenac sustained release matrix tablets using hydrophilic and hydrophobic polymers. Gandhiji and Ramesh 15 developed hydroxy propyl

methyl cellulose polymer based sustained release tablets of aceclofenac and found that they released drug over a period of 24 h. The results of the present work are in agreement with these reports, in that polymers, specifically PEOs, may be used for prolonging the drug release from matrix tablets. The present work, further, establishes, in human volunteers, that the drug is available in blood over a period of 24 h. The results of the present study clearly demonstrated the successful preparation of once daily, sustained release matrix tablets of aceclofenac, employing polyethylene oxides of different molecular weights, as controlled release polymers. The formulation F10, comparable to a marketed SR formulation, Hifenac SR, was developed and found to be giving effective and safe plasma concentration time profile up to 24 h. All authors have none to declare. “
“Staphylococcus aureus (S. aureus) resistant to methicillin is a major problem that the world is now facing.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>